The population of Europe is projected to become older in the coming decades, with an uneven growth rate expected in the various countries. The percentage of the total population age 65 years or older is predicted to increase from 17% in 2008 to 23.5% in 2030. According to the EUREYE study, 3.3% of the European population age 65 years or older has AMD . The prevalence is 40% higher in women than men and rises steeply with age. This indicates approximately 2.5 million AMD cases within the 27 EU nations. Data from the International Diabetes Federation show that there are currently 55 million adults and 112,000 children with diabetes in Europe; 10 million to 12 million more cases are expected by 2030.
(Reuters) - Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date. Glaucoma affects about 2.7 million people in the United States and is the second leading cause of blindness in the world. Rhopressa helps lower the pressure due to a build up of fluid in the eye by targeting the trabecular meshwork, the main drain through which fluid flows out of the eye. For more details: New breakthrough in ophthalmology